Phase 3
Completed N=45
Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With GPP
Source: ClinicalTrials.gov NCT05352893 ↗Enrolled (actual)
45
Serious AEs
2.2%
Results posted
Mar 2026
Primary outcomePrimary: Percentage of Patients Achieving a GPPPGA Score of 0 (Clear) or 1 (Almost Clear) — 8; 8; 2 Participants
◆ Published Evidence
Not yet cited
0citations
Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis.
Summary
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of imsidolimab compared with placebo in adult subjects with generalized pustular psoriasis (GPP).
Linked Publications
-
Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Patients Achieving a GPPPGA Score of 0 (Clear) or 1 (Almost Clear) |
8; 8; 2 | — |
| SECONDARY Percentage of Patients Achieving a PRS Score of 0 (Clear) or 1 (Almost Clear) |
6; 10; 2 | — |
Eligibility Criteria
Inclusion Criteria
- Subject has a BSA affected with pustules (excluding palms and soles) ≥ 5%, a GPPPGA score ≥ 3 (moderate severity), and a PRS score ≥ 3 (moderate severity) at Day 1
Exclusion Criteria
- Subject has other form of psoriasis excluding psoriasis vulgaris
- Subject flare is so severe that patient's life is at risk
Data sourced from ClinicalTrials.gov (NCT05352893) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.